Circulating levels of CD34+ cells predict long-term cardiovascular outcomes in patients on maintenance hemodialysis

Autoři: Ahmad Baseer Kaihan aff001;  Manabu Hishida aff001;  Takahiro Imaizumi aff001;  Masaki Okazaki aff001;  Ahmad Naseer Kaihan aff002;  Takayuki Katsuno aff004;  Akihiko Taguchi aff005;  Yoshinari Yasuda aff001;  Naotake Tsuboi aff001;  Tomoki Kosugi aff001;  Shoichi Maruyama aff001
Působiště autorů: Department of Nephrology, Graduate School of Medicine, Nagoya University, Nagoya, Japan aff001;  Faculty of Medicine, Balkh University, Mazar-i-Sharif, Afghanistan aff002;  Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America aff003;  Department of Nephrology and Rheumatology, Graduate School of Medicine, Aichi Medical University, Nagakute, Japan aff004;  Department of Regenerative Medicine Research, Institute of Biomedical Research and Innovation, Kobe, Japan aff005;  Department of Nephrology, Fujita Health University Graduate School of Medicine, Toyoake, Japan aff006
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article


CD34+ cells maintain vascular homeostasis and predict cardiovascular outcomes. We previously evaluated the association of CD34+ cells with cardiovascular disease (CVD) events over 23 months, but long-term CVD outcomes in relation to levels of CD34+ cells in patients on maintenance hemodialysis are unclear. Herein, we analyzed the long-term predictive potential levels of CD34+ cells for CVD outcomes and all-cause mortality. Between March 2005 and May 2005, we enrolled 215 patients on maintenance hemodialysis at Nagoya Kyoritsu Hospital and followed them up to 12.8 years. According to the CD34+ cell counts, patients were classified into the lowest, medium, and highest tertiles. Levels of CD34+ cells were analyzed in association with four-point major adverse CV events (MACEs), CVD death, and all-cause mortality. In univariate analysis age, smoking habit, lower geriatric nutrition risk index, lower calcium × phosphate product, and lower intact parathyroid hormone were significantly associated with the lowest tertile. Whereas, in multivariate analysis, age and smoking habit were significantly associated with the lowest tertile. Among 139 (64.7%) patients who died during a mean follow-up period of 8.0 years, 39 (28.1%) patients died from CVD. Patients in the lowest tertile had a significantly lower survival rate than those in the medium and highest tertiles (p ≤ 0.001). Using multivariable analyses, the lowest tertile was significantly associated with four-point MACEs (hazard ratio 1.80, p = 0.023) and CVD death (hazard ratio 2.50, p = 0.011). In conclusion, our long-term observational study revealed that a low level of CD34+ cells in the circulation predicts CVD outcomes among patients on maintenance hemodialysis.

Klíčová slova:

C-reactive proteins – Cardiovascular diseases – Hemoglobin – Hypertension – Medical dialysis – Medical risk factors – Smoking habits


1. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, et al. Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int. 2004;65: 2380–2389. doi: 10.1111/j.1523-1755.2004.00657.x 15149351

2. Yasuda K, Kasuga H, Aoyama T, Takahashi H, Toriyama T, Kawade Y, et al. Comparison of percutaneous coronary intervention with medication in the treatment of coronary artery disease in hemodialysis patients. J Am Soc Nephrol. 2006;17: 2322–2332. doi: 10.1681/ASN.2005090958 16837633

3. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco M V., et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58: 353–362. doi: 10.1046/j.1523-1755.2000.00173.x 10886582

4. Moeslinger T, Spieckermann PG. Urea-induced inducible nitric oxide synthase inhibition and macrophage proliferation [Internet]. Kidney international. Supplement. 2001. pp. S2–8.

5. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63: 793–808. doi: 10.1046/j.1523-1755.2003.00803.x 12631061

6. Fujiyama S, Amano K, Uehira K, Yoshida M, Nishiwaki Y, Nozawa Y, et al. Bone Marrow Monocyte Lineage Cells Adhere on Injured Endothelium in a Monocyte Chemoattractant Protein-1-Dependent Manner and Accelerate Reendothelialization as Endothelial Progenitor Cells. Circ Res. 2003;93: 980–989. doi: 10.1161/01.RES.0000099245.08637.CE 14525810

7. Griese DP, Ehsan A, Melo LG, Kong D, Zhang L, Mann MJ, et al. Isolation and Transplantation of Autologous Circulating Endothelial Cells into Denuded Vessels and Prosthetic Grafts: Implications for Cell-Based Vascular Therapy. Circulation. 2003;108: 2710–2715. doi: 10.1161/01.CIR.0000096490.16596.A6 14597586

8. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, et al. Statin therapy accelerates reendothelialization: A novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002;105: 3017–3024. doi: 10.1161/01.cir.0000018166.84319.55 12081997

9. Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dimmeler S. Relevance of Monocytic Features for Neovascularization Capacity of Circulating Endothelial Progenitor Cells. Circulation. 2003;108: 2511–2516. doi: 10.1161/01.CIR.0000096483.29777.50 14581410

10. Carmeliet P. Angiogenesis in health and disease. Nature Medicine. 2003. pp. 653–660. doi: 10.1038/nm0603-653 12778163

11. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999;5: 434–438. doi: 10.1038/7434 10202935

12. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353: 999–1007. doi: 10.1056/NEJMoa043814 16148285

13. Fadini GP, Rigato M, Cappellari R, Bonora BM, Avogaro A. Long-term Prediction of Cardiovascular Outcomes by Circulating CD34 + and CD34 + CD133 + Stem Cells in Patients With Type 2 Diabetes. Diabetes Care. 2017;40: 125–131. doi: 10.2337/dc16-1755 27815289

14. Schmidt-Lucke C, R√∂ssig L, Fichtlscherer S, Vasa M, Britten M, K√§mper U, et al. Reduced Number of Circulating Endothelial Progenitor Cells Predicts Future Cardiovascular Events. Circulation. 2005;111: 2981–2987. doi: 10.1161/CIRCULATIONAHA.104.504340 15927972

15. Fadini GP, de Kreutzenberg S, Agostini C, Boscaro E, Tiengo A, Dimmeler S, et al. Low CD34+ cell count and metabolic syndrome synergistically increase the risk of adverse outcomes. Atherosclerosis. 2009;207: 213–219. doi: 10.1016/j.atherosclerosis.2009.03.040 19406403

16. Makino H, Miyamoto Y, Kikuchi-Taura A, Soma T, Taguchi A, Kishimoto I. Decreased levels of circulating CD34 + cells are associated with coronary heart disease in Japanese patients with type 2 diabetes. J Diabetes Investig. 2015;6: 473–478. doi: 10.1111/jdi.12310 26221527

17. Lee HJ o., Kim W, Kim WS hi., Woo JS hi., Kim YG yoo., Moon JY oun., et al. Circulating Endothelial Progenitor Cell Levels Predict Cardiovascular Events in End-Stage Renal Disease Patients on Maintenance Hemodialysis. Nephron. 2015;130: 151–158. doi: 10.1159/000430471 26089157

18. Maruyama S, Taguchi A, Iwashima S, Ozaki T, Yasuda K, Kikuchi-Taura A, et al. Low circulating CD34+ cell count is associated with poor prognosis in chronic hemodialysis patients. Kidney Int. Elsevier Masson SAS; 2008;74: 1603–1609. doi: 10.1038/ki.2008.495 18843254

19. Aragona CO, Imbalzano E, Mamone F, Cairo V, Lo Gullo A, D’Ascola A, et al. Endothelial progenitor cells for diagnosis and prognosis in cardiovascular disease. Stem Cells International. 2016. doi: 10.1155/2016/8043792 26839569

20. Di Stefano R, Chiara Barsotti M, Felice F, Magera A, Lekakis J, Leone A, et al. Smoking and Endothelial Progenitor Cells: A Revision of Literature. Curr Pharm Des. 2010; doi: 10.2174/138161210792062939 20550506

21. Dimmeler S, Vasa-Nicotera M. Aging of Progenitor Cells: Limitation for Regenerative Capacity? J Am Coll Cardiol. Elsevier Masson SAS; 2003;42: 2081–2082. doi: 10.1016/j.jacc.2003.09.016 14680730

22. Taguchi A, Matsuyama T, Moriwaki H, Hayashi T, Hayashida K, Nagatsuka K, et al. Circulating CD34-positive cells provide an index of cerebrovascular function. Circulation. 2004;109: 2972–2975. doi: 10.1161/01.CIR.0000133311.25587.DE 15184275

23. JOURDE-CHICHE N, DOU L, SABATIER F, CALAF R, CERINI C, ROBERT S, et al. Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients. J Thromb Haemost. 2009;7: 1576–1584. doi: 10.1111/j.1538-7836.2009.03540.x 19583820

24. Mandraffino G, Aragona CO, Cairo V, Scuruchi M, Gullo A Lo, D’Ascola A, et al. Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects. PLoS One. 2017; doi: 10.1371/journal.pone.0173030 28301500

25. Urbich C, Dimmeler S. Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney International. 2005. doi: 10.1111/j.1523-1755.2005.00261.x 15840010

26. Shantsila E, Watson T, Lip GYH. Endothelial Progenitor Cells in Cardiovascular Disorders. Journal of the American College of Cardiology. 2007. doi: 10.1016/j.jacc.2006.09.050 17306702

27. Hill JM, Zalos G, Halcox JPJ, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk. Obstet Gynecol Surv. 2004; doi: 10.1097/01.ogx.0000074096.62998.d7

28. Zampetaki A, Kirton JP, Xu Q. Vascular repair by endothelial progenitor cells. Cardiovascular Research. 2008. doi: 10.1093/cvr/cvn081 18349136

29. Van Der Valk FM, Kuijk C, Verweij SL, Stiekema LCA, Kaiser Y, Zeerleder S, et al. Increased haematopoietic activity in patients with atherosclerosis. Eur Heart J. 2017;38: 425–432a. doi: 10.1093/eurheartj/ehw246 27357356

30. Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 2018; doi: 10.1093/ndt/gfy174 30281132

31. Fadini GP, De Kreutzenberg SV, Coracina A, Baesso I, Agostini C, Tiengo A, et al. Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. Eur Heart J. 2006;27: 2247–2255. doi: 10.1093/eurheartj/ehl198 16912055

32. Taguchi A, Naritomi H, Soma T, Tanaka H, Kanda T, Nishimura H, et al. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest. 2004; doi: 10.1172/JCI20622 15286799

33. Valgimigli M, Rigolin GM, Fucili A, Della Porta M, Soukhomovskaia O, Malagutti P, et al. s. Circulation. 2004;110: 1209–1212. doi: 10.1161/01.CIR.0000136813.89036.21 15249502

34. Losordo DW, Kibbe MR, Mendelsohn F, Marston W, Driver VR, Sharafuddin M, et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv. 2012;5: 821–830. doi: 10.1161/CIRCINTERVENTIONS.112.968321 23192920

35. Henry TD, Schaer GL, Traverse JH, Povisc TJ, Davidson C, Lee JS, et al. Autologous CD34+ Cell Therapy for Refractory Angina: 2 year Outcomes from the ACT34-CMI Study. Cell Transplant. 2016;25: 1701–1711. doi: 10.3727/096368916X691484 27151378

Článek vyšel v časopise


2019 Číslo 10
Nejčtenější tento týden